HOME › Research Insight › CSL Ltd. (Australia), Grifols S.A (Spain) Baxalta Incorporated (U.S.), Octapharma AG (Switzerland), and Kedrion S.p.A (Italy) dominate the global Plasma Fractionation Market
CSL Ltd. (Australia), Grifols S.A (Spain) Baxalta Incorporated (U.S.), Octapharma AG (Switzerland), and Kedrion S.p.A (Italy) dominate the global Plasma Fractionation Market
The global plasma fractionation market is dominated by CSL Ltd. (Australia), Grifols S.A (Spain), Baxalta Incorporated (U.S.), Octapharma AG (Switzerland), and Kedrion S.p.A (Italy), which together accounted for ~65% to 70% of the global market in 2015. The rest of the market is fragmented in nature with the presence of many local and regional players.
The leading position of CSL Ltd. (Australia) in this market is majorly attributed to its diversified product portfolio, which includes a wide range of plasma products for bleeding disorders, neurological diseases, and immune diseases. Moreover, the company’s strong manufacturing and distribution capabilities, which enables it to serve customers across the globe further strengthens its position in the global plasma fractionation market. The company intends to further strengthen its market position and stabilize its financial growth by focusing on various growth strategies such as expansion. For instance, in October 2014, CSL Behring invested USD 450 Million for capacity expansion at its Broadmeadows facility (Melbourne, Australia) and Kankakee site (Illinois, U.S.) to increase the production of plasma derived products.
Grifols S.A (Spain) held the second-largest share in the plasma fractionation market in 2015. The company provides its products in more than 90 countries in the world. To maintain its leading position and enhance its market share the company focuses on various growth strategies such as expansions and agreements. For instance, in March 2016, the company invested USD 360 million to expand its manufacturing capacity for plasma derived products. In addition, in October 2015, Grifols opened its Biosciences divisions’ global operations center at Grange Castle Business Park Dublin, Ireland.
Baxalta Incorporated (U.S.) held the third-largest share in the plasma fractionation market in 2015. The company is well-positioned in the plasma fractionation market due to its expertise in medical devices, pharmaceuticals, and biotechnology. The company has manufacturing operations across 12 facilities and distributes products in more than 100 countries. The company emphasizes on strengthening its plasma product portfolio for various acute and chronic diseases through external innovation, acquisitions, asset purchases, in-licensing transactions, development, supply and distribution agreements and other strategic partnerships which will be complimented by ongoing internal R&D efforts. For instance, in January 2016, the company entered into a strategic collaboration with Symphogen A/S (Denmark) collaboration to build an innovative portfolio of immunotherapies.
Industry players adopted the strategy of expansions, and agreements, collaborations, and partnerships as major growth strategies to achieve growth in the global plasma fractionation market. In order to strengthen their market position and customer base, companies adopted expansions as a key growth strategy. This strategy also helped companies to garner larger market shares and strengthen their customer base and production capacities. CSL Ltd. (Australia), Grifols S.A. (Spain), Biotest AG (Germany) Octapharma AG (Switzerland), and Kedrion S.p.A (Italy) are some leading market players that adopted this strategy to develop their businesses. Besides expansions, companies adopted the strategy of agreements, collaboration and partnership, in order to expand their product portfolios and distribution networks. Some major players adopted this strategy are Grifols S.A. (Spain), LFB S.A. (France), Octapharma AG (Switzerland), Biotest AG (Germany), Kedrion S.p.A (Italy), and Baxalta Incorporated (U.S.).
Plasma Fractionation Market by Product (Albumin, Immunoglobulin, Factor VIII, Protease Inhibitors), Application (Neurology, Hematology, Rheumatology, Immunology), End User (Hospitals, Clinical Research Laboratories) - Global Forecast to 2021
Markets and Markets
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India